文献速递衰弱、肌少症与跌倒

SARC-F 筛查老年人肌少症的诊断准确性荟萃分析

SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy.
PubMed 文献 · J Am Med Dir Assoc · 2018-05-31

该荟萃分析纳入 7 项研究共 12800 名老年人,评估 SARC-F 对肌少症的筛查能力。以欧洲老年人肌少症工作组(EWGSOP)为标准时,合并灵敏度 0.21、特异度 0.90;SARC-F 灵敏度低但特异度高,可用于筛选需进一步确诊检查的对象。

要点

  • SARC-F 筛查肌少症灵敏度低(合并 0.21),单独用于排除诊断不可靠。
  • SARC-F 特异度高(合并 0.90),阳性者应进一步检查确诊肌少症。
  • 以 IWGS 和 AWGS 为标准时,合并灵敏度和特异度与 EWGSOP 结果相似。

核心结论

  • SARC-F 筛查灵敏度差但特异度高,适合用于筛选需进一步检查以确诊肌少症的对象。

研究设计与样本

  • 设计为荟萃分析,检索 MEDLINE、Cochrane 系统综述数据库和 ClinicalTrials.gov 中 1960 年及以后发表、含 SARC-F 诊断肌少症灵敏度和特异度数据的研究。
  • 共纳入 7 项研究、合计 12800 名受试者。
  • 采用双变量随机效应模型计算合并灵敏度、特异度、阳性似然比(PLR)、阴性似然比(NLR)和诊断比值比(DOR),并用汇总受试者工作特征曲线总结总体检验性能。

主要发现

  • 以欧洲老年人肌少症工作组(EWGSOP)为标准时,合并灵敏度为 0.21(95%CI 0.13-0.31),特异度为 0.90(95%CI 0.83-0.94)。
  • 以 EWGSOP 为标准时,合并 PLR 为 2.16(95%CI 1.51-3.09),NLR 为 0.87(95%CI 0.80-0.95),DOR 为 2.47(95%CI 1.64-3.74)。
  • 以国际肌少症工作组(IWGS)和亚洲肌少症工作组(AWGS)为标准的研究,合并灵敏度和特异度与 EWGSOP 结果相似。
  • 使用 Foundation National Institute of Health 标准的研究较少,未进行荟萃分析。

关键数值与推荐

  • 以 EWGSOP 为参考标准时,SARC-F 合并灵敏度 0.21(95%CI 0.13-0.31)、特异度 0.90(95%CI 0.83-0.94)。
  • 以 EWGSOP 为参考标准时,合并 PLR 2.16(95%CI 1.51-3.09)、NLR 0.87(95%CI 0.80-0.95)、DOR 2.47(95%CI 1.64-3.74)。

临床怎么用

  • SARC-F 阳性(提示肌少症风险)者应进一步接受确诊性检查,而非直接诊断肌少症。
  • 不宜单独依靠 SARC-F 阴性结果排除肌少症,因其灵敏度低。

局限性

  • 使用 Foundation National Institute of Health 参考标准的研究较少,未能进行荟萃分析。
  • 原文未报告纳入研究的异质性、发表偏倚等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the screening ability of SARC-F for older adults using a meta-analysis. DESIGN: Meta-analysis. SETTING AND PARTICIPANTS: The literature review was conducted using MEDLINE, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov. Articles written on and after 1960 that included data regarding the sensitivity and specificity of SARC-F's diagnostic criteria for sarcopenia in older adults were searched. MEASURES: The bivariate random effects model was used to calculate the summary estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The summary receiver operating characteristic curve was used to summarize the overall test performance. RESULTS: Seven studies involving a total of 12,800 subjects met the eligibility criteria of our study. The pooled results of sensitivity, specificity, PLR, NLR, and DOR with the European Working Group on Sarcopenia in Older People as the reference standard were 0.21 [95% confidence interval (CI), 0.13-0.31], 0.90 (95% CI, 0.83-0.94), 2.16 (95% CI, 1.51-3.09), 0.87 (95% CI, 0.80-0.95), and 2.47 (95% CI, 1.64-3.74), respectively. Overall, we achieved similar pooled results of sensitivity and specificity for studies using the International Working Group on Sarcopenia and Asian Working Group for Sarcopenia as the reference standards. Because few studies used the Foundation National Institute of Health reference standards, a meta-analysis was not performed. CONCLUSIONS/IMPLICATIONS: Although the screening sensitivity performance of SARC-F was poor, its specificity was high; thus, it is an effective tool for selecting subjects who should undergo further testing for confirming a diagnosis of sarcopenia.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Ida S, Kaneko R, Murata K, et al. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc. 2018. PMID: 29778639. doi:10.1016/j.jamda.2018.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。